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a b s t r a c t
Components from venoms have stimulated many drug discovery projects, with some notable successes.
These are brieﬂy reviewed, from captopril to ziconotide. However, there have been many more disap-
pointments on the road from toxin discovery to approval of a new medicine. Drug discovery and
development is an inherently risky business, and the main causes of failure during development pro-
grammes are outlined in order to highlight steps that might be taken to increase the chances of success
with toxin-based drug discovery. These include having a clear focus on unmet therapeutic needs,
concentrating on targets that are well-validated in terms of their relevance to the disease in question,
making use of phenotypic screening rather than molecular-based assays, and working with development
partners with the resources required for the long and expensive development process.
© 2014 The Author. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
1. Introduction
While venoms featured in several systems of traditional healing,
the modern translation of toxins into medicines began in the 1940s
with the introduction of tubocurarine into anaesthetic practice as a
selectively actingmuscle relaxant (Bowman, 2006). Tubocurarine is
one of the key active ingredients in curare, the South American
arrow poison. By binding to nicotinic acetylcholine receptors at the
neuromuscular junction, tubocurarine blocks the transmission of
excitatory signals from motor nerves to skeletal muscles, causing
muscle paralysis. Use of tubocurarine allowed patients undergoing
major surgery to be paralysed without using dangerously high
doses of general anaesthetics. Although this revolutionised anaes-
thetic practice, the search soon began for new agents that lacked
the cardiovascular side effects of tubocurarine. Since tubocurarine
was known to have a relatively rigid core structure carrying two
functional groups, most discovery work focused on synthetic
compounds with curarimimetic actions: the toxin provided the
template for drug design. Relatively little work involved explora-
tions of other toxins that could cause paralysis. However, the most
successful of the new muscle relaxants, atracurium, did draw on
naturally-occurring curare-like alkaloids (Stenlake et al., 1983). Two
relatively innocuous moieties were chemically linked to form the
active molecule. The chemical bridge was designed to break down
rapidly in plasma in order to provide elimination that was not
dependent on liver or kidney function and to give a short-acting
agent to facilitate the control of the duration of the paralysis. By
chance, atracurium lacks the cardiovascular side effects of other
muscle relaxants (blockade of nicotinic receptors in sympathetic
ganglia that leads to a pronounced fall in blood pressure, and/or
block of muscarinic cholinoceptors innervated by the cardiac vagus
that could trigger arrhythmias). Atracurium was introduced in
1983, followed by cis-atracurium (a deﬁned isomer) in 1995.
Other sources of arrow poisons, notably extracts of frog skin,
were studied in the 1970s and ‘80s. While many compounds with
interesting pharmacological actions were discovered (Daly, 1982;
Philippe and Angenot, 2005), none has led to a successful medi-
cine. However, the discovery of epibatidine and its analgesic effects
indicated that neuronal nicotinic receptors could be a possible
therapeutic target. Structurally related compounds were tested by
the Abbott company, including tebanicline (ABT-594) that reached
phase II clinical trials before being dropped because of its side ef-
fects (Arneric et al., 2007).
There was, however, a notable success from research on snake
venoms, namely the development of captopril, the inhibitor of
angiotensin converting enzyme (ACE). This work was based on
small peptides from the venom of the South American snake
Bothrops jararaca that were known to potentiate the action of
bradykinin (for reviews, see Opie and Kowolik, 1995; Camargo et al.,
2012). Although bradykinin potentiating peptides are not toxins in
the sense of having a potentially lethal action, they do come from a
venom of a snake that is dangerous to humans. Work in Brazil and
London explored the concept that bradykinin potentiating peptides
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could inhibit the enzyme that was responsible for the production of
vasoactive angiotensin (Smith and Vane, 2003). The hypothesis was
that systemic blood pressure would be lowered by blocking
angiotensin converting enzyme. This was demonstrated experi-
mentally and in humans with the synthetic bradykinin potentiating
peptide teprotide in 1971. However, teprotide had to be injected, an
obvious disadvantage for treating patients with high blood pres-
sure. Considerable effort led to the orally acting ACE inhibitor
captopril, which was introduced in 1981 (Cushman et al., 1977).
Since then, many follow-up compounds have been introduced.
2. More recent successes
Captopril's success is generally credited as triggering the
recognition that venoms could be the source of new medicines
(Harvey, 1992; Lewis and Garcia, 2003; Fox and Serrano, 2007;
Shaw, 2009; King, 2011; Koh and Kini, 2012; Takacs and Nathan,
2014), but further successes have been rare. While snake venoms
were recognised as the source of enzymes with speciﬁc actions on
many of the components in the blood clotting cascade (Kornalík,
1991), there were no further developments of non-enzymatic
compounds until the almost simultaneous introduction of eptiﬁ-
batide and tiroﬁban in 1998. These act on GPIIb/IIIa integrin re-
ceptors on blood platelets to prevent platelet aggregation and
thrombus formation. Clinically, they are used in patients with acute
coronary syndrome and in high-risk patients undergoing coronary
interventions. Both compounds owe their existence to research on
snake venoms. Eptiﬁbatide is a synthetic cyclic heptapeptide that
mimics the action of a much larger peptide (73 amino acids) found
in the venom of the southeastern pigmy rattlesnake Sistrurus mil-
iarius barbouri. Tiroﬁban is not a peptide but it is based on a 49-
residue polypeptide from a snake venom, echistatin from the
saw-scaled viper Echis carinatus. Both compoundswere designed to
mimic the RGD sequence that is the recognitionmotif for binding to
GPIIb/IIIa integrin receptors (Hashemzadeh et al., 2008).
More recently, venoms from sources other than snakes have
attracted attention. Venoms from marine cone snails (Conus) have
been proposed as promising sources of new drug leads (e.g., Lewis
and Garcia, 2003; Twede et al., 2009; Essack et al., 2012; Vetter and
Lewis, 2012) because they contain a rich variety of small peptides
with diverse pharmacological actions. Ziconotide, the synthetic
version of the venom peptide MVIIA from Conus magus, was
approved by the FDA in 2004 for treating patients with intractable
pain. The compound selectively blocks N-type calcium ion channels
(Cav2.2); when administered intrathecally, it can reduce pain
transmission in the spinal cord (Pope and Deer, 2013).
Sometimes included as successes in drug discovery and devel-
opment from venom components are compounds inspired by
molecules that are not exactly toxins and from sources that are not
exactly venoms. Examples include variants of hirudin, the antico-
agulant thrombin antagonist from the saliva of the medicinal leech,
Hirudo medicinalis and exenatide, the GLP-1 agonist peptide from
the saliva of the Gila monster lizard, Heloderma suspectum that is in
use as an anti-diabetic agent (King, 2011; Takacs and Nathan, 2014).
Arguably, the biggest successes in translating toxins to products
in recent years have been the developments from the microbial
botulinum toxins. Both botulinum toxins A and B have been
approved for clinical use to treat patients with a variety of condi-
tions caused by over-activity of neurones. By restricting the toxins'
actions by localised injections and through their highly selective
uptake into particular nerves, botulinum toxins have been used
successfully in, e.g., strabismus, blepharospasm, dystonias, hyper-
hidrosis and migraine (Abrams and Hallett, 2013; Matak and
Lackovic, 2014). Of course, many sales are derived from the use of
botulinum preparations for cosmetic purposes, but further
therapeutic applications have been proposed (Dolly et al., 2011). In
recent developments, a topical formulation of botulinum toxin A
(RT001) was efﬁcacious in a double-blind trial to treat facial
wrinkles (Glogau et al., 2012) and another topical formulation
(ANT-1207) is currently in phase II clinical trials (http://
clinicaltrials.gov/show/NCT01293552; http://clinicaltrials.gov/
show/NCT01358695).
3. Trials and tribulations
Earlier reviews on the potential of toxin-related compounds
have lists of products in clinical trials (King, 2011; Takacs and
Nathan, 2014). Unfortunately, several of these products have since
been dropped, illustrating how difﬁcult it can be to go from
promising effects in animal studies to beneﬁcial and side-effect-
free actions in humans.
Following the example of the conopeptide ziconotide, other
Conus peptides have been pursued. A calcium ion channel blocker
from Conus catus, u-conotoxin CVID (variously named AM336,
CNSB004 and leconotide) failed in clinical trials because of side
effects encountered; these trials involved intrathecal administra-
tion, but the peptide was to be tried again using intravenous
administration (Kolosov et al., 2010). However, the company
responsible for the development, Relevare Pharmaceuticals, is in
liquidation (https://insolvencynotices.asic.gov.au/browsesearch-
notices/notice-details/Relevare-Pharmaceuticals-Ltd-142658259)
The a-conotoxin Vc1.1 (ACV1) from Conus victoriae failed because of
lack of efﬁcacy: while this compound was identiﬁed as an antag-
onist of subtypes of neuronal nicotinic cholinoceptors, it was sub-
sequently shown to have analgesic potential by acting through a
rather different mechanism, that of activating GABA-B receptors
and causing a decrease in calcium ion currents in nociceptive
neurones (Adams and Berecki, 2013). Xen2174, the synthetic
analogue of the c-conopeptide Mr1A from Conus marmoreus, in-
hibits noradrenaline reuptake in neurones and has profound
analgesic activity in animal studies (Lewis, 2012); however, it was
also found to have dose-limiting toxicity in humans despite early
promise in Phase I trials (Groeneveld, 2013).
Chlorotoxin from the venom of the scorpion Leiurus quinques-
triatus was ﬁrst identiﬁed as a blocker of some chloride ion chan-
nels and then found to inhibit matrix metalloproteinases (Deshane
et al., 2003). It showed promise as a means to identify glioma
tumour cells and, potentially, as away to localise anti-cancer agents
to such tumour cells (Wu et al., 2010). However, clinical trials with
chlorotoxin and conjugates with 131I appear to have been sus-
pended (http://clinicaltrials.gov/ct2/show/NCT00733798)
following a takeover of the development company.
Some compounds featured in earlier review articles do still
appear to be under active investigation. A snake venom natriuretic
peptide DNP (from greenmamba Dendroaspis angusticeps) has been
fusedwith human C-type natriuretic peptide to provide amolecule,
CD-NP or cenderitide, that activates both A and B forms of the
natriuretic peptide receptor, with the expectation that this would
give both improved efﬁcacy and a longer duration of action in pa-
tients with heart failure (McKie et al., 2010; Vink et al., 2012). A
clinical trial assessing the pharmacokinetics, pharmacodynamics,
safety and tolerability of subcutaneous administration of cenderi-
tide in patients with chronic heart failure has been completed and a
pilot study for the preservation of left ventricular function in pa-
tients after myocardial infarction is underway (https://clinicaltrials.
gov/ct2/show/NCT02071602).
A synthetic peptide ShK-186 related to the potassium ion
channel blocker ShK from the sea anemone Stichodactyla helianthus
(Chi et al., 2012) is also in early-stage clinical trials (company
website: http://www.kinetabio.com/autoimmune.html). The
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modiﬁed peptide is more speciﬁc than the native peptide for the
Kv1.3 subtype of voltage-activated potassium ion channels (Beeton
et al., 2011). These channels are important for the activation of T-
cells in autoimmune diseases. Blocking the channels by ShK-186
may be efﬁcacious in multiple sclerosis and other autoimmune
diseases.
Most of the agents described above reached clinical trials
because of their highly selective mechanism of action, e.g. ShK-186
blocks Kv1.3 subtypes of potassium ion channels but not any of the
closely related voltage-activated potassium ion channels. It is,
therefore, perhaps surprising that tetrodotoxin, which blocks most
subtypes of sodium ion channels, is also in clinical trials. Most of the
clinical work has been in Canada with patients suffering from se-
vere cancer-related pain (Hagen et al., 2007, 2008, 2011). Results
show some promise, with some patients noting improvements in
symptoms, but more extensive testing may prove to be more
demanding.
The US biotechnology company ReceptoPharm reports that it
has completed phase I clinical trials with detoxiﬁed versions of a-
cobrotoxin (isolated from the venom of the cobraNaja nivea) and a-
cobratoxin (from the venom of Naja kaouthia) (company website:
http://www.receptopharm.com/drug_development/pipeline.php).
In vitro studies showed that modiﬁed toxin or detoxiﬁed cobra
venoms stimulated the production of cytokines, including inter-
feron-g, by human T-cells (US Patent, 2010). The company is
intending to conduct further clinical trials in multiple sclerosis,
motor neurone disease, adrenomyeloneuropathy and viral
infections.
4. Still to come?
As mentioned earlier, venoms from Conus marine snails are
enthusiastically regarded as sources of drug leads. A bioinformatics
approach led the authors to highlight “98 recently identiﬁed con-
otoxins with therapeutic potential” (Essack et al., 2012). Earlier
discussions focused on neuro- and cardio-protective conopeptides,
including conantokins that block NMDA receptors and several po-
tassium ion channel blockers (Twede et al., 2009). Their develop-
ment was being undertaken by the US biotechnology company
Cognetix that has subsequently closed (King, 2011). Other con-
opeptides targeting sodium ion channels and various receptors (for
acetylcholine, neurotensin, noradrenaline and 5-
hydroxytryptamine) have been highlighted by Vetter and Lewis
(2012). Little is known about their progress towards clinical
development. A m-conotoxin (XEP-018) from Conus consors venom
was reported to bemoving into preclinical development on account
of its particularly long duration of action (St€ocklin, 2012) but its
current status is unknown.
While Conus venoms have attracted most attention, venoms
from other sources are also being explored. Various scorpion,
spider, bee and wasp venoms have provided toxins that have been
tested experimentally for effects that could relate to therapeutic
beneﬁt (Klint et al., 2012; Mortari and Cunha, 2013). There are
many reports of positive results on animal models of pain and
epilepsy, but there have not yet been clinical developments. The
French biotechnology company Theralpha reported intentions to
develop a spider toxin PcTx1 as a potential analgesic because of its
speciﬁc effects on ASIC1a ion channels, one of the acid sensing
channels; however, Theralpha appears to have gone out of
operation.
Snake venoms also continue to be explored for molecules with
therapeutic potential (e.g. King, 2011; Earl et al., 2012; Koh and Kini,
2012; Vink et al., 2012). Several compounds of interest come from
venoms of Australian snakes, and their potential applications
include preventing bleeding (textilin-1, Q8008), reducing blood
loss and haemorrhage (pseudotarin C components, Haempatch and
CoVase), and reversing congestive heart failure (natriuretic pep-
tides from Taipan venom). These seem to have had a troubled
commercial history. Textilin-1, Haempatch and CoVase were being
developed by the Australian company QRx Pharma, and were the
basis of a joint venture agreement between the subsidiary company
Venomics and a Chinese company Liaoning Nuokang Medicines
Company Ltd in 2009: no development has been reported recently.
The natriuretic peptides were to be developed by another Austra-
lian company ElaCor, but this company was delisted in 2010
(Commonwealth of Australia Gazette, 2010). An earlier develop-
ment that was based on another component from Taipan venom,
Oxynor, was reported to be in clinical development for wound
healing (Lipps, 2004), but the company responsible for this, Ophidia
Products, no longer seems to be operational.
Vicrostatin, a chimeric protein based on the disintegrins echis-
tatin and contortrostatin, inhibits angiogenesis and is being tested
in animal models as the basis of an anti-cancer agent (Minea et al.,
2012). Development will take place through the start-up company
Applied Integrin Sciences Inc.
Snake venoms have also provided components that have anal-
gesic actions in animal models. For example, the a-neurotoxin
hannalgesin from venom of the king cobra Ophiophagus hannah (Pu
et al., 1995) was the basis of a small peptide named prohanin (US
Patent, 2003). Despite being based on the sequence of an a-
neurotoxin and, hence, of a nicotinic cholinoceptor antagonist,
prohanin does not paralyse skeletal muscles, but appears to act as
an analgesic via involvement of nitric oxide synthase and to be well
absorbed sublingually (US Patent, 2003; US Patent Application,
2012). Prohanin was reported to be in preclinical development
(Koh and Kini, 2012; US Patent Application, 2012). Unfortunately,
the development was to be carried out by the company Theralpha
that has closed (RM Kini, personal communication, 2014).
Venom of the South American rattlesnake Crotalus durissus
terriﬁcus also has analgesic actions in experimental animals, even
on oral administration (Giorgi et al., 1993). A 14-residue peptide
with one disulphide bridge is involved. This peptide, named cro-
talphine, has been studied extensively (e.g. Konno et al., 2008;
Zambelli et al., 2014). Some of its actions are mediated through
k-opioid receptors, with an involvement of pathways including
nitric oxide (Gutierrez et al., 2012) and cannabinoids (Machado
et al., 2014). Crotalphine is being treated as a possible develop-
ment candidate (US Patent Application, 2009) and is currently in
the pre-clinical phase with the Brazilian company Biolab
Farmaceutica.
More recently, peptides with analgesic actions were identiﬁed
in the venom of the black mamba snake, Dendroaspis polylepis
polylepis (Diochot et al., 2012). The active compounds are novel
members of the three-ﬁnger toxin family, although they are not
themselves toxic in mice. The compounds, named mambalgins,
block acid-sensing ion channels (ASICs) in peripheral and central
neurons, and are active in a variety of pain models (Diochot et al.,
2012; Baron et al., 2013). The mambalgins were to be developed
by Theralpha.
Another potential mechanism for an analgesic effect is to block
the Nav1.7 subtype of sodium ion channels, and a highly selective
blocker of this channel type has been found in the venom of the
centipede Scolopendra subspinipes mutilans (Yang et al., 2013). The
active component is a 46-residue peptide named m-SLPTX-Ssm6a,
and it is hoped that this may be a lead to a novel class of
analgesics.
Outside of medicines development, a spider-derived peptide
directed at ion channels has been approved by the Environmental
Protection Agency in the USA as a potential insecticide (see com-
pany website http://www.vestaron.com/epa-approval/).
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5. Where do drugs come from?
In the last 30 years, the FDA has approved 1355 new drugs
(Newman and Cragg, 2012) and 1453 in all years up to 2013 (Kinch
et al., 2014). From the discussions above, it is clear that very few of
these are toxins or are derived or inspired by toxins or venom
components: atracurium, captopril, eptiﬁbatide, tiroﬁban, zicono-
tide and several botulinum toxin products. Despite that, publica-
tions from toxinologists continue to include optimistic statements
about the beneﬁts of toxins as starting points for drug discovery
and development. Also, it is sometimes stated that ‘biologics’ as
opposed to conventional small molecules appear to be gaining
favour with development companies and with regulatory author-
ities. The large-molecule NMEs (generally proteins and peptides)
have had a higher success rate than small-molecule NMEs: 13.2%
comparedwith 7.6% (Hay et al., 2014). However, the largemolecules
include growth factors and other substitutes for endogenous pro-
teins. These would be expected to succeed in clinical development.
In overall terms, while the numbers of approved small molecule
drugs (‘NewMolecular Entities’) appear more or less stable over the
last 10 years, the number of therapeutic biologics (as opposed to
others such as vaccines and protein-based diagnostic agents) is not
on a consistently upward trend between 2004 and 2013 (Fig. 1).
Moreover, the number of biotechnology companies involved in
FDA-approved medicines has been decreasing in recent years
(Kinch, 2014a,b).
It has also been pointed out that toxin-related peptides are
frequently very stable (because of their intramolecular disulphide
bridges), that large-scale synthesis of peptides is becoming feasible,
and that drug delivery systems are being developed for peptides
(King, 2011; Vetter and Lewis, 2012). These advantages have yet to
be seen in clinical development: a reviewof biologics in clinical trial
or under examination by the FDA identiﬁed 907 products (PhRMA,
2013). Approximately half were vaccines and other products that
would not be categorised as ‘therapeutic biologics’. Of the
remainder, the vast majority were monoclonal antibodies; there
were very few peptides or proteins. The only toxin-related products
were seven involving different forms of botulinum toxin A.
While the numbers of therapeutic biologics are not particularly
increasing in recent years, a more serious concern is the relatively
low number of new medicines in total (Fig. 1). There were 39
approved by the FDA in 2012, butmost years have been closer to the
annual average for 2004 to 2013 of 26. This seems a disappointing
return on the annual investment of more than $50 billion in
worldwide pharmaceutical research and development.
What factors contribute to the success or failure of drug dis-
covery and development projects, and is it possible for toxinolo-
gists to learn from them?
Kola and Landis (2004) analysed the reasons why compounds
failed during development. Their study covered compounds being
developed by 10 large pharmaceutical companies in the period of
1991e2000. The overall success rate from phase I clinical trials to
approval was 11%. The main reasons for compounds being dropped
were lack of efﬁcacy (~30% of failures), toxicity concerns (~30%),
and commercial issues (~20%). A more recent analysis of failures in
phase II and III clinical trials showed that 56% failed because of lack
of efﬁcacy, 28% because of safety issues, and 12% for strategic or
commercial reasons (Arrowsmith and Miller, 2013). A recent and
more comprehensive survey of success rates during development
covered over 4000 compounds from 835 companies between 2003
and 2011 (Hay et al., 2014). The overall success rate in going from
phase I trials to gaining FDA approval was 10.4%, with lack of efﬁ-
cacy remaining the main cause of failures. Clearly, there are still
major problems along the path from discovery to market.
The reasons for the high attrition rates have been analysed and
debated (e.g. Pammolli et al., 2011; Swinney and Anthony, 2011;
Allison, 2012; Morgan et al., 2012; Scannell et al., 2012; Sams-
Dodd, 2013; Cook et al., 2014; Eder et al., 2014). These follow on
from the suggestions made earlier (Kola and Landis, 2004) of ways
to reduce attrition: early validation that the proposed therapeutic
target does play a critical role in the pathophysiology of the disease;
using appropriate animal models in preclinical studies; avoiding
compounds that havemechanism-based toxicity; using biomarkers
in early clinical trials to conﬁrm that appropriate dosing has been
achieved in order to hit the compound's molecular target;
improved design of proof-of-concept clinical trials; and better
alignment of R&D with market and competitor analyses.
While design of clinical trials can be improved (Allison, 2012), it
seems that there needs to be a critical appraisal of the drug dis-
covery and candidate selection process. Given that many com-
pounds are failing through lack of efﬁcacy in the clinic, the links
between drug discovery screening and the actual disease being
Fig. 1. New drugs approved by the FDA. BLAs ¼ therapeutic biologics (ﬁled under Original Biologic License Applications); NMEs ¼ drugs with small molecule active ingredients
(New Molecular Entities).
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targeted must be weak. With the rapid adoption of the techniques
of high-throughput screening, much of drug discovery is based on
selecting single molecular targets as the basis for the screening
assay. Despite advances in genomics and other modern techniques,
it is still difﬁcult to be sure that modulating a single molecular
target will affect the course of the disease. A bioassay based on a
functional or systems approach may be more likely to reﬂect the
pathophysiology of the disease, but such approaches are less suit-
able for screening large numbers of compounds.
An analysis of the 75 novel (‘ﬁrst-in-class’) drugs approved by
the FDA between 1999 and 2008 emphasised the importance of
using functional (or ‘phenotypic’) assays (Swinney and Anthony,
2011). Twenty-eight of the 50 small-molecule NMEs came from
phenotypic screens, while 17 were from target-based assays and
ﬁve were modiﬁcations of known natural products. A further 25
approved compounds were biologics or large-molecule NMEs:
these can be taken as originating through target-based screening
because theywere created tomodulate a knownmolecular activity.
This analysis of ﬁrst-in-class drugs approved by the FDA was
extended to 2013 (Eder et al., 2014). A larger proportion of new
drugs originated from target-based screening, but 30% still came
from systems-based assays.
It is further argued that the pharmaceutical industry has shifted
from a focus on the patient and disease to one ﬁxed on the process
of drug discovery linked to using molecular targets in high-
throughput assays (Sams-Dodd, 2013). This may be compounded
by a desire to maintain a particular rate of progression of com-
pounds through different stages of drug development (Cook et al.,
2014). Consequently, the design of the drug discovery platform
must match the disease in question, and particularly the selection
of molecular targets becomes the critical step. However, this is
often based on incomplete or imperfect knowledge of the disease.
Target-based drug discovery also rests largely on the assumption
that modulating a single molecule will inﬂuence the disease, but
this is rarely the case in practice (Hopkins et al., 2006; Scannell
et al., 2012). The high rate of clinical failures implies that targets
are not sufﬁciently validated or that the intermediate step of
functional testing in an animal model of the disease relies on non-
predictive surrogates for the human disease (Morgan et al., 2012;
Sams-Dodd, 2013; Cook et al., 2014).
Going beyond these somewhat technical considerations,
Scannell et al. (2012) discuss other hurdles blocking the path to
drug approval. They argue that the on-going fall in productivity of
drug development (as measured by the number of drugs approved
per R&D expenditure) is unlikely to be completely stemmed simply
by improvements in technology. Two additional issues are high-
lighted. The ﬁrst is termed the ‘better than the Beatles’ problem,
which is that new drugs in many therapeutic areas have to achieve
a very high standard for acceptance because they have to compete
with older agents that are efﬁcacious, well-understood by pre-
scribers and likely to be much cheaper (because they may be off-
patent). Scannell et al. (2012) also point out that the regulatory
hurdles for drug approvals are consistently getting higher, making
it more and more difﬁcult for successful development of new
compounds. With society's expectations that new medicines
should be completely safe, this problem is unlikely to diminish.
6. Lessons for toxinologists?
Given that specialist biotechnology and pharmaceutical com-
panies struggle to undertake successful drug discovery and devel-
opment, it is hardly surprising that academic toxinologists have
difﬁculties. However, by considering carefully the evidence from
the successes and failures of others, toxinologists may leave behind
their naïve optimism for their lab-based discoveries and apply their
undoubted skills and insights more productively.
6.1. Starting with the toxin
Given that many new toxins are found because of their in-
teractions with speciﬁc proteins, particularly enzymes, ion
channels or receptors, there is a natural tendency for toxin-based
drug discovery to be created around the expectation (or hope?)
that the toxin's target protein is critical for the expression of a
particular disease. Before proceeding too far down the path to
establishing a drug development project, great care should be
given to assessing the evidence for the clinical relevance of the
target. It also should be remembered that the putative target is
likely to be expressed at several sites in the body. Hence, there is
always the possibility that the toxin will have unexpected and
unwanted effects in vivo.
As mentioned earlier, few diseases are caused by dysfunction of
single genes. Therefore, a highly speciﬁc toxin may not have much
impact on the overall pathophysiological process. However, the
‘translatability’ of a putative target can be assessed (Wehling, 2009)
and there are some promising examples in recent toxin studies.
Mutations in the human gene SNC9A that encodes a sub-unit of the
Nav1.7 sodium ion channel is associated with individuals' percep-
tion of pain. A screening programme based around testing venoms
on currents through Nav1.7 sodium ion channels uncovered a
potent and highly selective blocking peptide (Ssm6a) from a
centipede (Yang et al., 2013). This peptide was active in three mice
models of pain, and may, therefore, be a potential drug develop-
ment prototype.
6.2. Starting from the disease
Another approach is to work backwards from a disease to create
an appropriate screening programme. In this case, care should be
taken to make sure that the disease represents signiﬁcant unmet
therapeutic needs and the nature of the competitive landscape
should be deﬁned. Scannell et al. (2012) postulate that a focus on
cancer or on neglected diseases may be fruitful because the ‘better
than the Beatles’ problem will be less when there are few existing
treatments to contend with and because the attitudes of the reg-
ulatory authorities may be more encouraging towards new de-
velopments in these areas. Others have suggested that small-scale
clinical trials in rare diseases may be a route to rapid approval and
can lead to broader uses of the drugs for more common diseases
(Fishman and Porter, 2005; Kocher and Roberts, 2014).
In addition, it may be more productive to base the screening
campaign on phenotypic assays rather than on single molecular
targets. With venoms and toxins, there are unlikely to be thousands
of samples to be tested so high-throughput approaches should not
be essential. The validity of phenotypic assays still needs to be
rigorously assessed before being implemented (Horrobin, 2003;
Wehling, 2009; Zheng et al., 2013).
The original phenotypic screen for effect of venoms is the
envenomed victim: close observation of the signs and symptoms
during envenoming could reveal some unusual pharmacological
activity caused by a component of the venom. Knowledge that
envenoming by certain snakes was accompanied by severe
persistent pain led to the ﬁnding of a dimeric complex (MiTx) from
the venom of the Texas coral snake Micrurus tener tener that acti-
vated some ASIC channels in vitro and induced pain-like behaviour
in mice (Bohlen et al., 2011). Further screening of venoms resulted
in ﬁnding potent and highly selective blockers of relevant ASIC
channels (Diochot et al., 2012). In turn, these might be drug
development leads.
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Previously, observations of envenomed experimental animals
indicated the presence of novel toxins. The unusual appearance of
mice following injections with green mamba (D. angusticeps)
venom prompted further pharmacological investigations that
found the potassium ion channel blocking dendrotoxins and the
inhibitor of acetylcholinesterase activity, fasciculin (Harvey et al.,
1984). Comparison of effects of Conus venoms in mice following
intravenous or intracerebroventricular injection revealed different
behavioural phenotypes that guided the isolation of novel con-
opeptides (for example, Olivera et al., 1985).
For ethical, practical and scientiﬁc reasons, random screening of
venoms in mice would no longer be considered. However, it may be
possible to screen for novel activities using model organisms (such
as nematodes (Caenorhabditis elegans) and zebraﬁsh (Danio rerio)
that have found some use in other drug discovery projects
(Giacomotto and Segalat, 2010; Delvecchio et al., 2011; Asnani and
Peterson, 2014; Bruni et al., 2014). Various zebraﬁsh lines are
available to allow effects on speciﬁc developmental and physio-
logical process to be readily studied in transparent embryos in 96-
well plates, and model systems for a wide range of human tumours
are being developed in zebraﬁsh (Mimeault and Batra, 2013). With
the on-going interest in venom components as potential anti-
cancer agents the latter might be particularly attractive.
Although zebraﬁsh embryos have been increasingly used in
toxicological and pharmacological studies (e.g., to screen for anti-
epileptic compounds from medicinal plants, Challal et al., in
press), their use is too new to have provided clear evidence of
their ability to predict efﬁcacy in humans. Additional experimental
models are still going to be required to aid the reliable translation of
drug candidates from the lab to the clinic. In the oncology area, for
example, these models might be studies in patient-derived tu-
mours in immunocompromised mice or genetically engineered
mouse models that come close to resembling human tumours (see
the review by Cook et al., 2012).
Cell-based systems are also used for phenotypic screening. Ef-
fects can be changes in cell morphology, rate of cell multiplication,
or signalling behaviour. For example, many studies with venoms
and toxins have used cancer cell lines, although these may be poor
predictors of effectiveness on tumours in patients. Primary cultures
derived directly from patients may be more reliable (Cree et al.,
2010). Recent papers have highlighted the use of cultured neuro-
nes to detect effects of various venoms and toxins on ion channels
(Yang et al., 2013; Imperial et al., 2014).
6.3. Find a partner with deep pockets
Although some universities may be able to afford to pay for drug
development programmes (Christini, 2012), academics typically
need external funding in order to see their toxin enter the devel-
opment process. Such funding can come from investment into a
start-up company or through collaboration with an existing
biotechnology company (direct links with major pharmaceutical
companies on toxin-based drug discovery and development seem
to be rare). In all cases, patience and deep pockets are necessary. In
the USA, the average time from the formation of a biotechnology
company to its ﬁrst FDA approval was 11.3 years (Kinch, 2014a).
Hence, such companies need substantial funds from investors over
a protracted period. The lack of success of companies founded in
Europe and Australia to develop toxin-based drugs might, in part,
be because of difﬁculties in obtaining the necessary investment.
Even in USA, there are concerns for the health of the early-stage
drug discovery endeavour: fewer biotechnology companies are
being created than previously (Kinch et al., 2014) and there are
fewer venture capital investments going into companies with
products that are only in preclinical development (Christini, 2012).
The investment focus has shifted to companies with products in at
least phase II clinical trials. Similarly, pharmaceutical companies
are not tending to partner as often as before with biotechnology
companies at the preclinical stage.
6.4. Reasons to be cheerful
Despite all the caveats expressed above, it should be remem-
bered that academic researchers have made substantial contribu-
tions to successful drug developments. An analysis of the 144 FDA-
approved NMEs from 1998 to 2003 showed that 26 were associated
with inventions made in a university or public research organisa-
tion; in the same period, six of the 26 approved new biological
entities were based on university inventions (Kneller, 2005). When
the analysis was extended to 2007, it covered 252 new drugs, of
which 24% originated from university patents (Kneller, 2010).
With appropriate selection of disease target, toxin and partner,
further successes will emerge from explorations of the drug-like
potential of toxins.
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